A Phase 1/2 of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Status:
Not yet recruiting
Trial end date:
2026-08-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK,
PD, and anti-tumor activity of MRTX1133 in patients with advanced solid tumor malignancy
harboring a KRAS G12D mutation.